Medicago and its partner GlaxoSmithKline could be on track to have a Phase III readout for their COVID-19 vaccine candidate by summer, which the Canadian company hopes would also demonstrate the efficacy of its plant-based vaccine platform.
Its approach is unlike any other COVID-19 vaccine developer: its proprietary technology uses the Australian tobacco plant N benthamiana as...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
